EP0455770A1 - Use of guanidinoacetic acid to induce an increase of the creatine contents in muscles - Google Patents

Use of guanidinoacetic acid to induce an increase of the creatine contents in muscles

Info

Publication number
EP0455770A1
EP0455770A1 EP90917057A EP90917057A EP0455770A1 EP 0455770 A1 EP0455770 A1 EP 0455770A1 EP 90917057 A EP90917057 A EP 90917057A EP 90917057 A EP90917057 A EP 90917057A EP 0455770 A1 EP0455770 A1 EP 0455770A1
Authority
EP
European Patent Office
Prior art keywords
creatine
guanidinoacetic acid
methionine
gaa
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90917057A
Other languages
German (de)
English (en)
French (fr)
Inventor
Francesco Saverio Dioguardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0455770A1 publication Critical patent/EP0455770A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Definitions

  • creatine phosphate which is in relationship with ATP in the sense that between the two compounds there is an exchange of phospate groups.
  • the importance of creatine is demonstrated by the fact that in conditions of myocardial ischemia there is an arrest of the contractile function of the heart at the moment of the depletion of the creatine itself while 30% of the ATP is still present. This is due to the fact that the ATP available to give immediate energy for the contraction is only a small part of the ATP present, which functions as a reserve.
  • the duty of creatine is to recharge the ATP until it can give energy for the contraction. From these considerations an important problem clearly emerges, that is, the problem of increasing, when necessary, the amount of creatine in the muscle.
  • said substance is of great interest both in the medical and sports field: one only has to think, for example, of how many lives could be saved in case of myocardial infarct if it would be possible to make the cardial contractions continue in conditions of ischemia until a correct oxigenation of the infarcted tissue is restored or, in the case of sports activity, how well an athlete could perform in a sport with such an explosive type of effort, as in the 100 meter race, where the athlete carries out his performance in apnea.
  • Such an administration brings an increase of the intercellular muscular content of creatine and therefore • increases the availibility of energy for both the skeletal and cardiacal muscular cells.
  • GAA guanidinoacetic acid
  • SAMe sulpho-adenosyl-methionine
  • the experimentation with GAA was realized in two stages each of a week's duration, and intervalled by a period of three days between the first and second stage.
  • the creatininuria was monitored in the rats fed with a diet which contained methionine in an amount equal to the one needed by the rat plus an amount of methionine of 1.7 mg/kg of body weight, which corresponds to the one necessary to activate the GAA which will be added in the successive weeks.
  • the rats were fed with the diet of the preceding week supplemented with GAA in quantity of 1.7 mg/kg of body weight.
  • Such substances are also usefully administered to athletes who practice sports which require explosive efforts.
  • the adminsitration of GAA and of the GAA-methionine or GAA-SAMe association can be 5 made orally or parenterally employing said substances in a pure state or in the form of compositions comprising diluents and pharmacologically acceptable excipients.
  • GAA can be used as such or in the form of salt with a pharmacologically acceptable cation.
  • the daily dose of GAA to be administered is comprised between 10 0.0001 to 5 mg/kg of body weight in several daily doses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP90917057A 1989-11-27 1990-11-26 Use of guanidinoacetic acid to induce an increase of the creatine contents in muscles Withdrawn EP0455770A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2252089 1989-11-27
IT02252089A IT1237519B (it) 1989-11-27 1989-11-27 Impiego dell'acido guanidinacetico per indurre un incremento del contenuto muscolare di creatina

Publications (1)

Publication Number Publication Date
EP0455770A1 true EP0455770A1 (en) 1991-11-13

Family

ID=11197371

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90917057A Withdrawn EP0455770A1 (en) 1989-11-27 1990-11-26 Use of guanidinoacetic acid to induce an increase of the creatine contents in muscles

Country Status (4)

Country Link
EP (1) EP0455770A1 (it)
AU (1) AU6732190A (it)
IT (1) IT1237519B (it)
WO (1) WO1991007954A1 (it)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
CA2078019C (en) * 1991-09-13 2002-08-27 Siegbert Heinrich Bissbort Substance or composition and uses thereof
GB9215746D0 (en) * 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
WO1994026261A1 (en) * 1993-05-14 1994-11-24 Amira, Inc. Treating body parts susceptible to ischemia using creatine analogs
DE19537494C2 (de) * 1995-09-25 1997-10-02 Desitin Arzneimittel Gmbh Kreatin zum Schutz von neuralem Gewebe
ATE457726T1 (de) * 2002-06-19 2010-03-15 Nutricia Nv Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen
DK1758463T3 (da) 2004-06-09 2008-05-05 Alzchem Trostberg Gmbh Guanidinoeddikesyre som fodermiddeltilsætning
US8536222B2 (en) 2005-03-04 2013-09-17 Alzchem Ag Addition compounds of guanidinoacetic acid
DE102005009990A1 (de) * 2005-03-04 2006-09-07 Degussa Ag Salze, Anlagerungs- und Komplexverbindungen der Guanidinoessigsäure
RU2422049C2 (ru) * 2005-08-02 2011-06-27 Альцхем Тростберг Гмбх Жидкая композиция, основанная на компоненте гуанидинуксусной кислоты
DE102006009373A1 (de) * 2006-03-01 2007-09-06 Degussa Gmbh Fertigfutter für Haustiere
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
DE102007034102A1 (de) * 2007-07-21 2009-01-22 Alzchem Trostberg Gmbh Abriebfeste und rieselfähige Glycocyamin-haltige Formlinge und Verfahren zu deren Herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9107954A1 *

Also Published As

Publication number Publication date
IT8922520A1 (it) 1991-05-27
IT1237519B (it) 1993-06-08
WO1991007954A1 (en) 1991-06-13
AU6732190A (en) 1991-06-26
IT8922520A0 (it) 1989-11-27

Similar Documents

Publication Publication Date Title
Zarembski et al. Some factors influencing the urinary excretion of oxalic acid in man
Uzbay et al. A modified liquid diet of chronic ethanol administration: validation by ethanol withdrawal syndrome in rats
US5767159A (en) Method of increasing creatine supply depot
EP0455770A1 (en) Use of guanidinoacetic acid to induce an increase of the creatine contents in muscles
Freis et al. Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents
Bohl et al. Magnesium and exercise
Brooks et al. The refeeding syndrome: an approach to understanding its complications and preventing its occurrence
Stokes et al. Prazosin: preliminary report and comparative studies with other antihypertensive agents
EP1087779A2 (en) Compositions for increasing energy in vivo
WO1992006686A1 (en) New method of treating depression
Berndt et al. Effects of parathyroid hormone and calcitonin on electrolyte excretion in the rabbit
Kraut et al. Effect of colchicine and calcitonin on calcemie response to metablic acidosis
Manitius et al. Some observations on the influence of a magnesium-deficient diet on rats, with special reference to renal concentrating ability
BELL et al. Studies of 47Ca metabolism in acromegaly
EP0231768B1 (en) A composition of amino acids
Krasner Cardiac effects of magnesium with special reference to anaesthesia: a review
Windsor et al. The effect of whole-bone extract on 47Ca absorption in the elderly
v Eiff et al. The protective mechanism of estrogen on high blood pressure
Boris et al. Inhibition of diphosphonate-blocked bone mineralization. Evidence that calcitonin promotes mineralization
Beard The biochemistry of creatine and creatinine
Alter et al. A new guanidine diuretic, amipramizide: reduction of the kaliuretic effect of ethacrynic acid in man
Zataraín et al. Rhabdomyolysis and acute renal failure associated with lovastatin
US5530003A (en) Pharmaceutical compositions for curing rheumatism
Draper Physiological aspects of aging: V. Calcium and magnesium metabolism in senescent mice
CA2082275A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19911205

17Q First examination report despatched

Effective date: 19930208

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930619